All enrolled sufferers who acquired no less than a person dose of zosuquidar or placebo throughout induction were monitored for that incidence of adverse activities (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse events were being related to the duration of prolonged and major myelosuppression https://charlesi666zlv9.national-wiki.com/user